In order to attain durable and broad antitumor response, phase Ib clinical trials have been conducted in several arms to evaluate combinatorial treatments of MRTX849 with such inhibitors, afatinib (RTK inhibitor in NSCLC patients), cetuximab (EGFR inhibitor in metastatic CRC patients), and pembrolizumab (PD-1/PD-L1 inhibitor in NSCLC patients). Here, EGFR is linked to non-small cell lung carcinoma.